Active Plasminogen Activator Inhibitor 1 (PAI1)
SERPINE1; PLANH1; Serpin Peptidase Inhibitor Clade E Member 1; Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1; Endothelial plasminogen activator inhibitor
- UOM
- FOB US$ 274.00 US$ 684.00 US$ 1,368.00 US$ 4,104.00 US$ 10,260.00
- Quantity
Overview
Properties
- Product No.APA532Hu61
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsCell culture; Activity Assays.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathwayHematology
- Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
- Traits Freeze-dried powder, Purity > 95%
- Isoelectric Point7.5
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
Activity test
Plasminogen Activator Inhibitor 1 (PAI1) is a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI 1 is the principal inhibitor of urokinase type plasminogen activator (uPA) and tissue type PA. As important regulators of extracellular matrix remodeling, uPA and PAI 1 play a major role in many processes such as angiogenesis, tumor invasion and obesity. Besides, Vitronectin (VTN) has been identified as an interactor of PAI1, thus a binding ELISA assay was conducted to detect the interaction of recombinant human PAI1 and recombinant human VTN. Briefly, PAI1 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl were then transferred to VTN-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-PAI1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of PAI1 and VTN was shown in Figure 1, and this effect was in a dose dependent manner, the EC50 was approximately 4.47 ug/mL.
Usage
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
Storage
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
Stability
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
Increment services
- BCA Protein Quantification Kit
- Molecular Mass Marker for Protein
- Monoclonal Antibody Customized Service
- Polyclonal Antibody Customized Service
- Protein Activity Test Experiment Service
- Electrophoretic Mobility Shift Assay (EMSA) Experiment Service
- Buffer
- Lentivirus Packaging Experiment Service
- Adenovirus Packaging Experiment Service
- Real Time PCR Experimental Service
- Spike RBD Protein (S-RBD)
- Protein G
- Protein A
Citations
- Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c miceSpringerLink: f3w831267267p277
- Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency?Pubmed: 24203351
- Trans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptorsPubMed: 25546502
- Activation of cardiac renin–angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorderPubmed:26934364
- Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expressionpubmed:27447455
- Combined oral contraceptive and nitric oxide synthesis inhibition synergistically causes cardiac hypertrophy and exacerbates insulin resistance in female rats.pubmed:28376377
- Alteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatmentpubmed:28249913
- Anti-inflammatory and antithrombotic effects of nicotine exposure in oral contraceptive-induced insulin resistance are glucocorticoid-independentpubmed:28349880
- Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domainPubmed:29903766
- Puerarin prevents vascular endothelial injury through suppression of NF-κB activation in LPS-challenged human umbilical vein endothelial cellsPubmed:29775893
- Impact of Regular Physical Activity on Adipocytokines and Cardiovascular Characteristics in Spinal Cord–Injured SubjectsPubmed:29548578
- Anticoagulant and Antithrombotic Properties in Vitro and in Vivo of a Novel Sulfated Polysaccharide from Marine Green Alga Monostroma nitidumPubmed: 31027312
- IKKβ regulates the expression of coagulation and fibrinolysis factors through the NF‑κB canonical pathway in LPS‑stimulated alveolar epithelial cells type IIPubmed: 31572531
- Sodium aescinate significantly suppress postoperative peritoneal adhesion by inhibiting the RhoA/ROCK signaling pathwayPubmed: 32120245
- Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasisPubmed:35013379
- Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: Implication for COPD drug …Pubmed:35121390